Use of an afucosylated cd20 antibody for the manufacture of a medicament for cancer treatment in combination with bendamustine

摘要

The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with bendamustine for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and bendamustine.